

Identification of Putative Immunologic Targets for Colon Cancer Prevention Based on Conserved Gene Upregulation from Preinvasive to Malignant Lesions

Elizabeth K. Broussard¹, Rachel Kim¹, Jesse C. Wiley¹, Juan Pablo Marquez¹, James E. Annis³, David Pritchard², and Mary L. Disis¹

Abstract

The length of time required for preinvasive adenoma to progress to carcinoma, the immunogenicity of colorectal cancer (CRC), and the identification of high-risk populations make development and testing of a prophylactic vaccine for the prevention of CRC possible. We hypothesized that genes upregulated in adenoma relative to normal tissue, which maintained increased expression in CRC, would encode proteins suitable as putative targets for immunoprevention. We evaluated existing adenoma and CRC microarray datasets and identified 160 genes that were ≥ 2 -fold upregulated in both adenoma and CRC relative to normal colon tissue. We further identified 23 genes that showed protein overexpression in colon adenoma and CRC based on literature review. Silencing the most highly upregulated genes, *CDH3*, *CLDN1*, *KRT23*, and *MMP7*, in adenoma and CRC cell lines resulted in a significant decrease in viability ($P < 0.0001$) and proliferation ($P < 0.0001$) as compared to controls and an increase in cellular apoptosis ($P < 0.05$ for *CDH3*, *KRT23*). Results were duplicated across cell lines representing microsatellite instability, CpG island methylator, and chromosomal instability phenotypes, suggesting immunologic elimination of cells expressing these proteins could impact the progression of all CRC phenotypes. To determine whether these proteins were immunogens, we interrogated sera from early stage CRC patients and controls and found significantly elevated CDH3 ($P = 0.006$), KRT23 ($P = 0.0007$), and MMP7 ($P < 0.0001$) serum immunoglobulin G in cases as compared to controls. These data show a high throughput approach to the identification of biologically relevant putative immunologic targets for CRC and identified three candidates suitable for vaccine development. *Cancer Prev Res*; 1–9. ©2013 AACR.

Introduction

Colorectal carcinoma (CRC) arises from progressive genetic alterations, and the progression from normal epithelium to adenoma to invasive carcinoma occurs over years (1). This time period offers a window for preventative interventions that target high-risk patients, such as those with a prior history of CRC, patients with multiple adenomas, or adenomas with a high risk of malignant transformation (i.e., villous histology or size > 1 cm). Chemoprevention targeting adenomas is feasible and

effective, as showed in multiple clinical trials of nonsteroidal anti-inflammatory drugs (NSAID) including selective COX-2 inhibitors and aspirin (2–7), but widespread application of the approach has been limited by the lack of patient compliance associated with daily drug dosing, adverse cardiovascular events, and gastrointestinal bleeding (8–11).

Active immunization as a cancer immunoprevention strategy offers several advantages to classic drug-based approaches. First, vaccines are administered over a short period of time without the need for daily dosing. Moreover, if successful, immunologic memory is generated ensuring a destructive adaptive cellular immune response poised to eliminate aberrant cells at the time they arise. Immune elimination of cells that had aberrantly expressed proteins, which were associated with cell growth or survival, could potentially impact CRC development or progression. T-memory cells, once vaccine primed, are active for years and can be boosted periodically with further periodic vaccinations. In addition, vaccines have largely been shown to be nontoxic. There have been numerous clinical studies immunizing cancer bearing patients against proteins expressed in the colon with limited to no adverse events (12–16). Prophylactic vaccines have had remarkable success in

Authors' Affiliations: ¹Tumor Vaccine Group, Center for Translational Medicine in Women's Health; ²Department of Pathology; and ³Quellos High Throughput Screening Core, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

Corresponding Author: Elizabeth K. Broussard, Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, 850 Republican Street, Seattle, WA 98109. Phone: 206-543-8557; Fax: 206-685-3128; E-mail: elizabethb@medicine.washington.edu

doi: 10.1158/1940-6207.CAPR-12-0484

©2013 American Association for Cancer Research.

preventing cancers of viral origin, such as hepatitis B (17) and human papillomavirus (18). A major barrier to the extrapolation of the success seen with prevention of viral malignancies to the prevention of CRC has been the lack of well defined, biologically relevant, and immunogenic proteins expressed early in the malignant transformation of the disease.

Data presented here shows a high throughput approach, combining both expression array analysis and siRNA screening, for the identification of proteins expressed in both adenomas and invasive carcinomas that impact cell growth and senescence. Further evaluation for immunogenicity via serologic screening for immunoglobulin G (IgG) antibodies can identify candidate antigens that are capable of stimulating an adaptive immune response.

Materials and Methods

Dataset selection for adenoma and colon carcinoma genes

We entered search terms "Human Colorectal Carcinoma" or "Human Colorectal Adenoma" in Gene Expression Omnibus or GEO (19) and Array Express (20). We excluded colorectal carcinoma (CRC; $n = 307$) and adenoma ($n = 47$) datasets based on a prospectively defined exclusion algorithm (Supplementary Fig. S1). Of the 9 remaining datasets, 3 examined gene expression in 53 adenoma samples and 8 examined gene expression in 437 CRC samples. The sample distribution included 57% stage I/II, 15% stage III, and 28% stage IV samples (Supplementary Table S1).

Dataset validation

We conducted box plot analyses of each log₂-transformed and normalized dataset, and confirmed alignment of median values across the arrays and the similarity of the interquartile range using R (v 2.14.2), Bioconductor limma module (3.11.1), and the OneChannelGUI R interface (v 1.22.2). Box plotting of GSE 15960 is shown in Supplementary Fig. S2A. Hierarchical clustering linkage (Supplementary Fig. S2B) and principal component analysis (Supplementary Fig. S2C) showed distinct expression profile characteristics that cluster the sample groups together. Multidimensional scaling was conducted with the clustered datasets and confirmed that normal colon samples maintained distinct expression profiles from adenoma or CRC (data not shown).

Each GEO dataset was individually analyzed for differential expression. The log ratio was determined for adenoma or CRC versus normal colon. We set the fold change criterion at 2-fold overexpression with a P -value less than 0.05 after a Benjamini-Hochberg correction for multiple testing. The differentially expressed genes (significantly different genes in red) were plotted against the rest of the dataset in a mean-average plot (Supplementary Fig. S2D), and datasets showed linear mean centering on 0. The differentially expressed genes within each dataset were exported from R, and inserted into adenoma or CRC gene lists. To identify genes across Affymetrix and

Illumina platforms, probes or probe sets were collapsed to the HUGO gene symbol present on the platform annotation. The gene symbols were intersected and we identified 14,915 genes present across all array platforms and experiments, and calculated the average differential gene expression. We identified 631 genes that were upregulated in adenoma and 490 genes that were upregulated in CRC; 160 genes were commonly upregulated in both the adenoma and CRC datasets (Table S2).


Cell lines

CRC phenotypes are represented by the following 6 cell lines: microsatellite unstable (MSI) by HCT116 (ATCC CCL-247) and LoVo (ATCC CCL-229) and, CpG island methylator phenotype (CIMP) by RKO (ATCC CRL-2577) and SW48 (ATCC CCL-231), and chromosome instability (CIN) by FET (donated by Dr. W. Grady, Fred Hutchinson Cancer Research Center, Seattle, WA) and SW480 (ATCC CCL-228). Adenomas are represented by the cell line AAC/SB10 (donated by Dr. C. Paraskeva, University of Bristol, Bristol, UK). ATCC conducts authentication testing using short tandem repeat (STR) DNA profiling of all cell lines, and cells received (HCT116, LoVo, RKO, SW48, and SW480) were used in all assays within 6 months of receipt or resuscitation. FET cells were authenticated by a tetranucleotide repeats assay, AAC/SB10 cells were authenticated by genotyping, and all cell lines were tested for mycoplasma (Agilent Technologies) before the use in all assays, and within 6 months of resuscitation. Cells were maintained at 37°C and 5% CO₂. Growth media for cell lines: DMEM+4.5g/l-glucose+l-glutamine (AAC/SB10), DMEM+4.5g/l-glucose+l-glutamine+NaPyr (FET), McCoy's 5A medium modified (HCT116), F-12K medium (LoVo), Eagle's MEM (RKO), Leibovitz's L-15 medium (SW48, SW480). All media were supplemented with 1% FBS (Benchmark) and penicillin/streptomycin (Cellgro).

siRNA and transfection

On day 1, cells were plated into a 96-well flat bottom plate (Corning). On day 2, cells were transfected with 10 μmol/L siRNA (Sigma) using lipofectamine RNAiMax reagent (Invitrogen). We targeted CDH3, KRT23, MMP7, and CLDN1 with a pool of 3 unique siRNA dimers targeting the same gene, pooled at equal molarity (final concentration 125 nmol/L). The target sequences for the siCDH3 duplex were #1 5'-CCAAUAUCUGUCCUGAAA[dT, dT]-3', #2 5'-GCAACUUUAUAAUUGA GAA[dT, dT]-3', #3 5'-GUUUAGCACUGAUAAUGAU[dT, dT]-3'; siCLDN1 duplex were #1 5'-CAGUCAAUUGCC AGGUACGA[dT, dT]-3', #2 5'-GUACGAAUUUUGGU CAGGCU[dT, dT]-3', #3 5'-CAGAUCAGU GCAAAGUCU[dT, dT]-3'; siKRT23 duplex were #1 5'-CUCAGAUUAUCUUCUCAU[dT, dT]-3', #2 5'-GAAUCAA GUCGAGCAUGA[dT, dT]-3', #3 5'-GAGUGAAGG-GACACGGGAA[dT, dT]-3'; siMMP7 duplex were #1 5'-CCAUUCUUUGGGUAUGGGA[dT, dT]-3', #2 5'-CAAA-CUC AAGGAGAU GCAA[dT, dT]-3', #3 5'-GAUGGUAGCA-GUCUAGGGA[dT, dT]-3'. To assess the impact of targeting more than one gene at a time, we combined all 4 siRNA sequences (siCDH3, siCLDN1, siKRT23, and siMMP7) into

Figure 1. siRNA silencing of CDH3, CLDN1, KRT23, and MMP7 (A–D) in adenoma and CRC cell lines significantly reduces cell viability. Cell viability of transfected CRC and adenoma cell lines was quantitated at 7 days and results are normalized to nontransfected cells (NT). All assays were done in quadruplicate, and cell lines are grouped by phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480). Calculated *P*-values are for differences in viability between NT and each phenotype. Error bars note standard deviation. NT, nontransfected cells (transfection with PBS), ***P* < 0.0001.



a pooled siRNA. All assays were conducted in quadruplicate. Transfections were conducted with negative control PBS and nontargeting control siRNA (MISSION SiRNA Universal Negative Control; Sigma), and positive control Kif11s (Sigma).

mRNA quantitation

RNA was collected 48 hours after transfection and reverse transcribed using SuperScript III First-Strand Synthesis System (Invitrogen). Real-time PCR was done on an Applied Biosystems 7900. Primers for CDH3, CLDN1, KRT23, and MMP7 were purchased from Applied Biosystems. All assays were conducted in triplicate, and mRNA quantitated after normalization for β -actin. Significance was calculated using the unpaired 2-tailed Student *t* test. We confirmed that siRNA targeting all tested genes resulted in significant (all *P* values < 0.05) mRNA reduction in all cells compared to nontargeting siRNA (Supplementary Fig. S3). Specifically, siCDH3 resulted in mRNA reductions of $58.4 \pm 7.7\%$ to $98 \pm 0.21\%$ compared to control siRNA (Supplementary Fig. S3A). For siCLDN1, mRNA reductions of $61.1 \pm 8.5\%$ to $89.8 \pm 2.3\%$ were achieved (Supplementary Fig. S3B). For siKRT23 mRNA reductions of $60.7 \pm 20.2\%$ to $97.6 \pm 0.25\%$ were achieved (Fig. S3C), and for siMMP7 mRNA reductions of $63.2 \pm 4\%$ to $96.1 \pm 0.95\%$ were achieved (Supplementary Fig. S3D).

Cell viability, proliferation, and apoptosis

FET, LoVo, and SW480 cells (1,000 cells/well), RKO (500 cells/well), SW48 (2,400 cells/well), HCT116 (4,000 cells/well), and AAC/SB10 (8,000 cells/well) were seeded in 96-well plates (Corning). Cell viability was determined at day 7

(Fig. 1) with Resazurin (Sigma) and quantitated using the Perkin-Elmer Wallac EnVision 2104 Multilabel Detector/Plate Reader at 600 nm (21). Proliferation was quantitated at 48 hours by proliferating cell nuclear antigen (PCNA) protein expression (Fig. 2), relative to expression in cells transfected with control nontargeting siRNA. Apoptosis measurements were optimized at 48 hours for AAC/SB10, LoVo, and RKO cells and at 72 hours for FET, HCT116, SW48, and SW480 cells using Caspase-Glo 3/7 (Promega), and luminescence was measured (Fig. 3) using the Perkin-Elmer Wallac EnVision 2104 Multilabel Detector/Plate Reader (21,22). All data are expressed as mean \pm SD of cells within the specific phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480; Adenoma: AAC/SB10).

Western blot analysis

For detection of serum IgG antibody responses in patients and controls, the serum was diluted 1:200. For quantitation of protein expression in cell lines, nontransfected and transfected cells were seeded in 6-well flat bottom plates (Corning). After 48 hours, the cells were lysed, protein quantitated using BCA Protein Assay Kit (Pierce Biotechnology) and boiled in Laemmli buffer (Bio-Rad). Proteins from cell lines or recombinant proteins were run on 10% SDS-Page gels, transferred to nitrocellulose, blocked with 3% milk, and incubated with antibody overnight at 4°C: CDH3 (polyclonal TA302124; Origene), CLDN1 (clone 1C5-D9; Novus), KRT23 (polyclonal 22460002; Novus), MMP7 (polyclonal NB300-1000; Novus), PCNA (polyclonal ab2426; Abcam). Recombinant human proteins were used as positive controls: CDH3 (Origene), CLDN1, KRT23,




Figure 2. siRNA silencing of CDH3, CLDN1, KRT23, and MMP7 (A–D) in adenoma and CRC cell lines significantly reduces cell proliferation. PCNA protein was quantitated in transfected CRC and adenoma cells. All assays are done in triplicate, cell lines are grouped by phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480), and results are normalized to tubulin and PCNA expression in csiRNA. Error bars note SD, and calculated *P*-values are for differences in PCNA expression in csiRNA and each phenotype. csiRNA (control nontargeting siRNA), ***P* < 0.0001.

and MMP7 (all from Abnova). Untreated HCT116 cells were lysed and loaded as PCNA positive control (23). Membranes were incubated with goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP antibody (Invitrogen), and developed (Amersham Biosciences). The intensity of bands was quantitated (Image J), normalized to tubulin (monoclonal 11H10; Cell Signaling Technology), and all assays were done in triplicate. Data are expressed as percent change relative to protein expression in nontargeting csiRNA. Each

colon cancer cell line was evaluated individually but results are combined and grouped by phenotype (MSI: LoVo, HCT116; CIMP: RKO, SW48; CIN: FET, SW480). The Western blot validated that siRNA specifically and markedly reduced protein expression of CDH3, CLDN1, KRT23, and MMP7 (Fig. S4A–G). Specifically, siCDH3 reduced protein expression by $38.8 \pm 9.7\%$ to $53.1 \pm 3.8\%$, siCLDN1 by $33 \pm 1.1\%$ to $73.4 \pm 2.8\%$, siKRT23 by $19.8 \pm 5.3\%$ to $33.8 \pm 1.9\%$, and siMMP7 by $33 \pm 7.9\%$ to $76.5 \pm 9.3\%$.





Figure 3. siRNA silencing of CDH3, CLDN1, KRT23, and MMP7 (A–D) in adenoma and CRC cell lines induces apoptosis. Transfected CRC and adenoma cells were assayed for cellular apoptosis and results were normalized to nontransfected cells (NT). All assays were conducted in quadruplicate, and cell lines are grouped by phenotype (MSI: HCT116, LoVo; CIN: SW48, RKO; CIMP: FET, SW480). Calculated *P*-values are for differences in apoptosis between NT and each phenotype. Error bars note SD. NT, nontransfected cells (transfection with PBS), **P* < 0.05, ***P* < 0.0001.

Figure 4. CDH3, KRT23, and MMP7 are immunogenic in patients with early stage CRC. Serum IgG was quantitated with indirect ELISA in 25 early stage CRC (stages 1 and 2) patients and 25 controls. The dotted line represents the cut-off or serum value of the mean plus 2 SD of controls for each protein. Closed circles represent CRC patient sera, open circles represent control sera, and horizontal bars represent mean serum values. Calculated *P*-values are for differences in mean serum responses, **P* < 0.05. Positive (+) and negative (–) antibody responses were validated with protein expression for CDH3 (B), KRT23 (D), and MMP7 (F). Positive controls were recombinant protein blotted with the monoclonal antibody (mAb) for the respective protein.



Evaluation of humoral immunity specific for CDH3, CLDN1, KRT23, and MMP7

Indirect ELISA was conducted as previously described (24) with the following modifications: recombinant proteins CDH3, CLDN1, KRT23, and MMP7 were diluted with carbonate buffer to a concentration of 1.0 µg/mL. A sample was defined as positive when serum IgG value was greater than the mean and 2 SDs of the control sera ($n = 25$) evaluated for each protein (Fig. 4A, C, and E). Positive responses were verified by Western blot analysis (Fig. 4B, D, and F). The sensitivity and specificity were 100% and 100% for CHD3, 100% and 62.5% for KRT23, and 100% and 100% for MMP7. The CLDN1 ELISA results could not be validated by Western blotting, and therefore the results are not shown.

Human subjects

The CRC patients ($n = 25$) ranged in age from 45 to 89 (median age 66.5), and 40% were female. Stage 1 (40%) and stage 2 (60%) CRC patient sera were included (HSD# 19394; University of Washington, Seattle, WA and Innovative Research). The normal donors ($n = 25$) ranged in age from 23 to 84 (median age 61.7), and 48% were female (Puget

Sound Blood Bank, Seattle, WA). All donors met criteria for blood donation and informed consent was obtained from each subject. All sera were aliquoted and stored at -80°C .

Statistical analysis

Differences in cellular viability, proliferation, apoptosis, protein and RNA expression, and human serum IgG responses were assessed using the unpaired 2-tailed Student *t* test. Differences in the incidence of positives in serum IgG responses were quantitated using Fisher exact test. The significance was set at $P < 0.05$ (GraphPad Prism v 5.0).

Results

Genes that are upregulated encoding overexpressed proteins and are conserved from adenomas to invasive carcinomas can be identified

We identified 631 genes from the adenoma datasets and 490 genes from the CRC datasets. A total of 160 genes (Supplementary Table S2) are present in both datasets. Of note, 2 of the most common CRC antigens, CEA and MUC1, did not meet the selection criterion of at least 2-fold overexpression with a *P*-value less than 0.05 in any of the

Table 1. Genes showing protein overexpression in colon CRC or AD

Gene	Protein overexpression	Fold increase	
		CRC	AD
CDH3	AD, CRC	21	31
KRT23	CRC	16	3
MMP7	AD, CRC	13	23
CLDN1	AD, CRC	12	5
ETV4	AD, CRC	7	5
CLDN2	AD, CRC	6	8
LGR5	AD, CRC	6	4
SLCO1B3	CRC	5	13
TGFBI	CRC	5	6
SLC7A5	CRC	5	3
STC2	CRC	5	3
FABP6	AD, CRC	4	3
LCN2	CRC	3	7
TROP2	CRC	3	6
BMP4	AD, CRC	3	4
PTP4A3	AD, CRC	3	4
SLC6A14	CRC	3	4
S100A11	AD, CRC	2	3
TNS4	CRC	2	3
WNT2	CRC	2	3
CA9	AD, CRC	2	2
FKBP10	CRC	2	2
IFITM3	AD, CRC	2	2

Abbreviation: AD, adenoma.

datasets evaluated. We have showed that overexpressed tumor-associated proteins can be immunogenic (24). For each of the 160 genes upregulated in adenoma and carcinoma, we searched PubMed (25) for protein overexpression using the terms "(gene name) human protein colorectal overexpression" or "(gene name) human protein colorectal adenoma overexpression." As of October 1, 2012, 65 published papers (Supplementary Table S3) document protein overexpression (via immunohistochemistry or Western blot) of 23 of the 160 genes in human adenoma and CRC (Table 1). We chose to further evaluate the 4 most highly upregulated genes identified from the microarray data for potential biologic function in adenoma and CRC cells. Relative to expression in normal colon, CDH3 was upregulated 21-fold in CRC and 31-fold in adenoma; KRT23 16-fold in CRC and 3-fold in adenoma; MMP7 13-fold in CRC and 23-fold in adenoma; CLDN1 12-fold in CRC and 5-fold in adenoma (Table 1).

siRNA silencing of CDH3, CLDN1, KRT23, and MMP7 in adenoma and CRC cell lines significantly reduces cell viability

MSI, CIN, CIMP, and adenoma cell lines showed a 49% to 89% reduction in viability after knockdown of all 4 genes (all P values < 0.0001). Specifically, relative to nontransfected

cells, cells transfected with siCDH3 showed reduced viability: $53.3 \pm 8.5\%$ (MSI), $75.5 \pm 6.6\%$ (CIMP), $81.0 \pm 8.4\%$ (CIN), and $88.9 \pm 2.4\%$ (adenoma; Fig. 1A). In cells transfected with siCLDN1 viability decreased by $69.9 \pm 6.0\%$ (MSI), $84.1 \pm 3.6\%$ (CIMP), $78.6 \pm 12.7\%$ (CIN), and $85.6 \pm 2.0\%$ (adenoma; Fig. 1B). In cells transfected with siKRT23 viability decreased by $57.8 \pm 10.2\%$ (MSI), $58.8 \pm 7.4\%$ (CIMP), $69.4 \pm 13.3\%$ (CIN), and $88.4 \pm 1.0\%$ (adenoma; Fig. 1C). In cells transfected with siMMP7 viability decreased by $49.4 \pm 7.0\%$ (MSI), $58.1 \pm 10.6\%$ (CIMP), $52.5 \pm 13.0\%$ (CIN), and $87.5 \pm 2.1\%$ (adenoma; Fig. 1D). Finally, in cells transfected with pooled siRNA from all 4 candidates, viability was similarly decreased by $50.9 \pm 8.9\%$ (MSI), $49.3 \pm 5.4\%$ (CIMP), $48.7 \pm 23.8\%$ (CIN), and $83.7 \pm 1.2\%$ (adenoma; Supplementary Fig. S5).

siRNA silencing of CDH3, CLDN1, KRT23, and MMP7 in adenoma and CRC cell lines significantly reduces cell proliferation

siRNA silencing of all 4 genes significantly (all P -values < 0.0001) inhibited cellular proliferation in adenoma and all CRC phenotypes. Specifically, siCDH3 decreased PCNA expression by $56.9 \pm 3.7\%$ (MSI), $67.3 \pm 3\%$ (CIMP), $55.5 \pm 5.7\%$ (CIN), and $65.7 \pm 7.2\%$ (adenoma; Fig. 2A) relative to PCNA expression in control siRNA. The siCLDN1 inhibited proliferation by $50 \pm 2.9\%$ (MSI), $61.4 \pm 3.9\%$ (CIMP), $41.4 \pm 3.4\%$ (CIN), and $63.1 \pm 3.7\%$ (adenoma; Fig. 2B). The siKRT23 reduced proliferation by $50.7 \pm 6.3\%$ (MSI), $51.1 \pm 4.1\%$ (CIMP), $49.7 \pm 5.9\%$ (CIN), and $50.6 \pm 5.9\%$ (adenoma; Fig. 2C). Finally, the siMMP7 inhibited PCNA expression by $49.2 \pm 2.8\%$ (MSI), $53.7 \pm 4.1\%$ (CIMP), $48 \pm 3.6\%$ (CIN), and $53.1 \pm 5.5\%$ (adenoma) compared to control (Fig. 2D)

siRNA silencing of CDH3, CLDN1, KRT23, and MMP7 in adenoma and CRC cell lines induces apoptosis

siRNA silencing of CDH3 increased cellular apoptosis in MSI (1.48 ± 0.2 , $P = 0.008$), CIMP (1.66 ± 0.2 , $P = 0.0007$), CIN (1.16 ± 0.05 , $P = 0.009$), and adenoma cells (2.54 ± 0.4 , $P < 0.0001$; Fig. 3A) relative to control of nontransfected cells. Knockdown of CLDN1 increased apoptosis in MSI (1.19 ± 0.1 , $P = 0.13$), CIMP (1.57 ± 0.1 , $P < 0.0001$), CIN (1.35 ± 0.1 , $P = 0.0001$), and adenoma (1.68 ± 0.1 , $P < 0.0001$; Fig. 3B). Silencing KRT23 increased apoptosis in MSI (1.35 ± 0.1 , $P = 0.03$), CIMP (1.54 ± 0.1 , $P < 0.0001$), CIN (1.31 ± 0.1 , $P < 0.0001$), and adenoma (2.04 ± 0.1 , $P < 0.0001$; Fig. 3C). Similarly, knockdown of MMP7 induced apoptosis in MSI (1.42 ± 0.3 , $P = 0.26$), CIMP (1.98 ± 0.1 , $P < 0.0001$), CIN (1.45 ± 0.1 , $P < 0.0001$), and adenoma cells (2.45 ± 0.1 , $P < 0.0001$) compared to control (Fig. 3D).

CDH3, KRT23, and MMP7 are immunogenic in patients with early stage CRC

We next determined whether these proteins were immunogenic by determining whether antigen-specific IgG could be detected. The serum responses in CRC patients to CDH3 were higher than serum responses in control patients (mean $2.75 \pm 0.4 \mu\text{g/mL}$ vs. $1.58 \pm 0.2 \mu\text{g/mL}$, $P = 0.006$; Fig. 4A).

The incidence in CRC patients was higher than in controls (52% vs. 0%, $P < 0.0001$). The serum responses in CRC patients to KRT23 were higher than serum responses in controls (mean $1.42 \pm 0.2 \mu\text{g/mL}$ vs. $0.54 \pm 0.1 \mu\text{g/mL}$, $P = 0.0007$; Fig. 4B). The incidence in CRC patients was higher than in controls (24% vs. 8%, $P < 0.0001$). The serum responses in CRC patients to MMP7 were higher than serum responses in controls (mean $1.74 \pm 0.3 \mu\text{g/mL}$ vs. $0.43 \pm 0.1 \mu\text{g/mL}$, $P < 0.0001$; Fig. 4C). The incidence in CRC patients was higher than in controls (40% vs. 4%, $P < 0.0001$). Antigen-specific antibody responses detected in either control donors or CRC patients could be validated by Western blot (Fig. 4B, D, F).

Discussion

Few immunogenic proteins have been identified for immunologic interventions in CRC. Furthermore, the biologic relevance of some of the most commonly exploited antigens in CRC, such as MUC-1 and CEA, is not well elucidated (13,14,16). Data presented here shows that existing microarray datasets provide a rapid method to identify genes upregulated in adenomas that maintain increased expression in carcinomas and that these genes encode proteins that are overexpressed in both adenoma and CRC. Silencing adenoma–CRC gene expression with siRNA in multiple cell lines suggests these proteins may impact cell viability, proliferation, and survival across all CRC phenotypes. Finally, we show that overexpressed proteins conserved from adenoma to CRC have the potential to stimulate an adaptive immune response in either control donors or CRC patients. This latter observation suggests that tolerance has been circumvented to these self-proteins and that boosting immunity against these proteins with active immunization may be possible.

The development of CRC is a complex process involving multiple molecular pathways. Selective pathways active in advanced disease are already initiated in early tumorigenesis (i.e., adenomas) and are, thus, rational targets for chemoprevention as well as therapy (26). Prior published studies have primarily focused on expression of genes in CRC relative to normal colon tissue. Of the 27 studies of gene expression profiling in CRC published between 1998 and 2008 (27), only 4 studies included colon adenoma (28–31) and only 2 studies examined gene expression across the continuum of normal tissue, adenoma, and CRC (28,30). Taken together these 2 studies included 13 adenoma, 29 CRC, and 42 normal colon samples, and identified only 56 genes that were upregulated in adenoma and CRC although MMP7 and CDH3, 2 of the proteins presented here, were identified in each of the studies. More recent publications have combined expression data from normal, adenoma, and CRC, but these investigations examined similarly small samples sizes ($n = 16$) or focused on the differential expression of individual genes (32–34). Here we present the largest sample size analyzed to date that includes normal, adenoma, and CRC tissues (153 normal, 53 adenoma, 437 CRC), filtered through a prospectively defined exclusion algorithm and stringent quality control metrics,

resulting in the identification of 160 genes as potential chemoprevention targets (Supplementary Table S2). Neither CEA nor MUC1, 2 common CRC targets used for immune modulation, met the expression criteria outlined. These 160 candidate genes may have great potential as prevention or therapeutic targets. Of the 23 proteins (Table 1) we identified from published studies as overexpressed in adenoma and/or CRC, overexpression of the following 8 proteins was an independent predictor of significantly decreased overall survival in CRC: CA9, CDH3, ETV4, LCN2, MMP7, PTP4A3, TNS4, and TROP2 (35–42). Association of protein expression with poor prognosis suggests that such expression confers a more aggressive phenotype. The potential biologic relevance of these genes was further supported by silencing gene expression in adenoma and CRC cell lines showing a significantly reduced viability, decreased proliferation, and increased apoptosis. The observation that these functional effects were showed across all 3 CRC phenotypes suggests that immune elimination of cells expressing these proteins could potentially have some impact on tumor growth or progression. MSI is present in 15% of CRC, CIMP tumors represent approximately 20% of CRC, and CIN is the most common phenotype, representing 50% to 85% of all CRC (43).

Active immunization against overexpressed cancer-related proteins can result in elimination of premalignant cells. Immunizing against ductal carcinomas *in situ* (DCIS) with a vaccine targeting HER2, an overexpressed protein present on the majority of DCIS, resulted in resolution of lesions in some women or eradication of HER2-expressing cells (44). Clinical data in the prevention or high-risk setting does not yet exist for CRC; however, preclinical studies targeting a single antigen MUC-1 suggest the immunoprevention of CRC is feasible. MUC1 is a cell surface associated glycoprotein overexpressed in the premalignant environment of inflammatory bowel disease (IBD) and in CRC. In MUC-1 transgenic mice, immunization against MUC1 generated both anti-MUC1 IgG and MUC1-specific cytotoxic T cells. Immunized animals showed a significant delay in the development of IBD as measured by the development of rectal prolapse ($P = 0.043$ as compared to controls), and 80% of immunized animals had complete protection against the development of CRC (45). Studies by our group have showed that overexpression of a self protein is an independent predictor of immunogenicity in multivariate analysis (46). Immunogenicity of CDH3, KRT23, and MMP7 in either cancer patients or control donors shows, for some reason, that tolerance has been circumvented to these antigens in some individuals. The observation that CDH3, KRT23, and MMP7 antibodies are found in higher levels in CRC patients than controls suggests that the presence of malignancy may increase exposure to these antigens resulting in further stimulation of specific immunity. If high levels of immunity were induced earlier in the transformative process from adenoma to carcinoma, perhaps the progression to invasive disease could be prevented or slowed. These 3 genes

function in the pathogenesis of intestinal tumor development, suggesting that they could be appropriate targets for immunoprevention. CDH3 is involved in maintaining cellular localization and tissue integrity. Epigenetic demethylation of the CDH3 promoter permits its ectopic expression very early in the colorectal adenoma–carcinoma sequence and persistence during invasive cancer. Induced expression of CDH3 in mucosal damage leads to an increased rate of crypt fission, a common feature of clonal expansion in gastrointestinal dysplasia (47). Upregulation of CDH3 in cancer is associated with increased proliferation (48). KRT23 is responsible for the structural integrity of epithelial cells, and important in modulating and controlling cellular signaling processes and apoptosis (49). KRT23 expression differentiates between microsatellite-stable (MSS) and microsatellite-unstable (MSI) colon cancers (50), with 88% of MSI tumors negative for KRT23 and 70% of MSS tumors with KRT23 overexpression. MMP7 is involved in the breakdown of extracellular matrix by degradation of basement membrane proteins laminin and collagen IV. MMP7 expression is correlated with tumor malignancy and liver metastasis of CRC (51).

Immunization programs against hepatitis B and human papillomavirus to prevent hepatocellular carcinoma and cervical, vulvar, and vaginal cancers, respectively, have been implemented worldwide and show significant clinical efficacy (17,18). Vaccines are important to prophylaxis, as they can generate immunologic memory, which would result in the elimination of cells that begin to develop a cancer "phenotype." To date targeting such self proteins, including MUC1, CEA, and HER2, has been nontoxic and safe (13,14,16,52,53). The identification of biologically relevant antigens expressed early in the onco-

genic process lays the foundation for the further testing of immunoprevention for CRC.

Disclosure of Potential Conflicts of Interest

M.L. Disis has ownership interest (including patents) in University of Washington. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: E.K. Broussard, J.C. Wiley, D.K. Pritchard, M.L. Disis

Development of methodology: E.K. Broussard, R.Y. Kim, D.K. Pritchard, J.P. Marquez, J. Annis, M.L. Disis

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.K. Broussard, R.Y. Kim, M.L. Disis

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.K. Broussard, R.Y. Kim, J.C. Wiley, D.K. Pritchard, J.P. Marquez, J. Annis, M.L. Disis

Writing, review, and/or revision of the manuscript: E.K. Broussard, R.Y. Kim, J.C. Wiley, D.K. Pritchard, M.L. Disis

Study supervision: E.K. Broussard, M.L. Disis

Acknowledgments

The authors thank Dr. W. Grady for donating the FET cell line, and Dr. C. Paraskeva for donating the AAC/SB10 cell line.

Grant Support

This publication was supported by HHSN261-200533000C N01-CN-53300 (M. Disis) and by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR000421 (E. Broussard). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding was provided from the Sonora Cancer Research Center SON-2011-1-02/CEN and the Marcos & Saide Cancer Foundation RASAMA-112MEX/PC1976 (J.P. Marquez).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 13, 2012; revised April 30, 2013; accepted May 1, 2013; published OnlineFirst May 16, 2013.

References

- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988;319:525–32.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 2000;342:1946–52.
- Bertagnoli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. *N Engl J Med* 2006;355:873–84.
- Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, et al. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. *J Natl Cancer Inst* 2009;101:267–76.
- Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. *Cancer Prev Res* 2011;4:655–65.
- Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 2011;378:2081–7.
- Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet* 2010;376:1741–50.
- Baron JA, Sandler RS, Bresalier RS, Lanasa A, Morton DG, Riddell R, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. *Lancet* 2008;372:1756–64.
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;352:1092–102.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;352:1071–80.
- Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. *Am J Med* 2011;124:426–33.
- Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. *Cancer Invest* 2003;21:341–9.
- Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. *Clin Cancer Res* 2006;12(3 Pt 1): 869–77.
- Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. *Clin Cancer Res* 2006;12(11 Pt 1):3416–24.

15. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. *Oncol Rep* 2008;20:1305-11.
16. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. *Cancer Immunol Immunother* 2011;60:1565-75.
17. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med* 1997;336:1855-9.
18. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med* 2009;361:1838-47.
19. <http://www.ncbi.nlm.nih.gov/gds>
20. <http://www.ebi.ac.uk/arrayexpress/>
21. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. *Proc Natl Acad Sci* 2012;109:9545-50.
22. Wu Y, Connors D, Barber L, Jayachandra S, Hanumegowda UM, Adams SP. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. *Toxicol In Vitro* 2009;23:1170-8.
23. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. *Clin Cancer Res* 2001;7:185-91.
24. Goodell V, McNeel D, Disis ML. His-tag ELISA for the detection of humoral tumor-specific immunity. *BMC Immunol* 2008;9:23.
25. <http://www.ncbi.nlm.nih.gov/pubmed/>
26. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. *Nat Rev Drug Discov* 2009;8:213-25.
27. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. *Cancer Treat Rev* 2009;35:201-9.
28. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. *Oncogene* 2002;21:4120-8.
29. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, et al. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. *Int J Colorectal Dis* 2009;24:209-18.
30. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. *Cancer Res* 2001;61:3124-30.
31. Kita H, Hikichi Y, Hikami K, Tsuneyama K, Cui ZG, Osawa H, et al. Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. *J Gastroenterol* 2006;41:1053-63.
32. Dai YC, Zhu XS, Nan QZ, Chen ZX, Xie JP, Fu YK, et al. Identification of differential gene expressions in colorectal cancer and polyp by cDNA microarray. *World J Gastroenterol* 2012;18:570-5.
33. Sena P, Mariani F, Marzona L, Benincasa M, Ponz de Leon M, Palumbo C, et al. Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. *Int J Oncol* 2012;41:260-6.
34. Wang W, Zhu W, Xu XY, Nie XC, Yang X, Xing YN, et al. The clinicopathological significance of REIC expression in colorectal carcinomas. *Histol Histopathol* 2012;27:735-43.
35. Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. *BMC Cancer* 2009;9:246.
36. Sun L, Hu H, Peng L, Zhou Z, Zhao X, Pan J, et al. P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. *Am J Pathol* 2011;179:380-90.
37. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. *J Pathol* 2003;200:568-76.
38. Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. *Clin Cancer Res* 2011;17:4331-40.
39. Fang YJ, Ju ZH, Wang F, Wu XJ, Li LR, Zhang LY, et al. Prognostic impact of ER β and MMP7 expression on overall survival in colon cancer. *Tumour Biol* 2010;31:651-8.
40. Mollevi DG, Aytes A, Padullis L, Martinez-Iniesta M, Baixeras N, Salazar R, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. *Br J Cancer* 2008;99:1718-25.
41. Albasri A, Al-Ghamdi S, Fadhil W, Aleskandarany M, Liao YC, Jackson D, et al. Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. *Oncogene* 2011;30:2997-3002.
42. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. *Int J Colorectal Dis* 2009;24:875-84.
43. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. *Gastroenterology* 2007;132:127-38.
44. Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma *in situ* of the breast. *Cancer Res* 2007;67:6531-4.
45. Beatty PL, Narayanan S, Gariepy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. *Cancer Prev Res* 2010;3:438-46.
46. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. *J Clin Oncol* 2006;24:762-8.
47. Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, et al. Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission *in vivo*. *Cancer Res* 2008;68:7760-8.
48. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. *Biochim Biophys Acta* 2012;1826:297-311.
49. Liffers ST, Maghnoij A, Munding JB, Jackstadt R, Herbrand U, Schulenburg T, et al. Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3epsilon. *BMC Cancer* 2011;11:137.
50. Birkenkamp-Demtroder K, Mansilla F, Sorensen FB, Kruhoffer M, Cabezon T, Christensen LL, et al. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers *in vivo* and impacts viability and proliferation *in vitro*. *Mol Oncol* 2007;1:181-95.
51. Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. *Oncology (Williston Park)* 2008;75:32-41.
52. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. *J Clin Oncol* 2002;20:2624-32.
53. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. *J Clin Invest* 2001;107:477-84.

Cancer Prevention Research

Identification of Putative Immunologic Targets for Colon Cancer Prevention Based on Conserved Gene Upregulation from Preinvasive to Malignant Lesions

Elizabeth K. Broussard, Rachel Kim, Jesse C. Wiley, et al.

Cancer Prev Res Published OnlineFirst May 16, 2013.

Updated version	Access the most recent version of this article at: doi: 10.1158/1940-6207.CAPR-12-0484
Supplementary Material	Access the most recent supplemental material at: http://cancerpreventionresearch.aacrjournals.org/content/suppl/2013/05/16/1940-6207.CAPR-12-0484.DC1

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/early/2013/06/07/1940-6207.CAPR-12-0484>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.